• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌的主动监测:概述与更新。

Active surveillance for prostate cancer: overview and update.

机构信息

Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave MG 408, Toronto, M4N 3M5, Ontario, Canada.

出版信息

Curr Treat Options Oncol. 2013 Mar;14(1):97-108. doi: 10.1007/s11864-012-0221-5.

DOI:10.1007/s11864-012-0221-5
PMID:23318986
Abstract

Low-risk prostate cancer: How I would treat it? Overtreatment of many conditions diagnosed by screening has become increasingly recognized as a contemporary malady associated with modern medicine's efforts at earlier detection. The diagnosis of low-grade prostate cancer clearly qualifies as an example of potential overdiagnosis and overtreatment. Active surveillance for low-risk prostate cancer is an attempt to reduce the overtreatment of the disease. The approach involves initial expectant management rather than immediate therapy. Curative treatment is deferred while the patient is monitored and offered for evidence of risk reclassification to a more aggressive form of the disease. The basis for this approach is substantial evidence confirming the long natural history of most prostate cancers. The objective is to balance the risks of overtreatment and associated adverse quality of life effects, against the risk of progression of disease and a missed opportunity for curative therapy. Low-risk prostate cancer is more accurately viewed as one of several risk factors for the patient harboring higher-grade disease, rather than a life-threatening condition. This approach is similar to that taken historically for so-called precancerous conditions, such as PIN or ASAP, where patients were managed with close follow-up but without radical intervention unless clear evidence of more aggressive disease is identified. Active surveillance is increasingly viewed as the management of choice for patients with very low-risk (low-grade, low-volume prostate cancer) and low-risk (low-grade but higher volume) disease.

摘要

低危前列腺癌

我会如何治疗?过度治疗许多通过筛查诊断的疾病已日益被认为是现代医学早期检测努力相关的当代弊病。低级别前列腺癌的诊断显然符合潜在过度诊断和过度治疗的例子。对低危前列腺癌的主动监测是减少该疾病过度治疗的一种尝试。该方法涉及初始的期待性管理,而不是立即进行治疗。在患者被监测并提供疾病风险重新分类为更具侵袭性形式的证据时,推迟了治愈性治疗。这种方法的基础是大量证据证实了大多数前列腺癌的长期自然史。其目的是平衡过度治疗和相关不良生活质量影响的风险,与疾病进展的风险和错过治愈性治疗的机会之间的平衡。低危前列腺癌更准确地被视为患者存在更高级别疾病的几个危险因素之一,而不是危及生命的疾病。这种方法类似于历史上对所谓癌前病变(如 PIN 或 ASAP)所采取的方法,其中患者通过密切随访进行管理,但除非明确发现更具侵袭性的疾病,否则不进行激进干预。主动监测越来越被视为非常低危(低级别、低体积前列腺癌)和低危(低级别但体积较高)疾病患者的治疗选择。

相似文献

1
Active surveillance for prostate cancer: overview and update.前列腺癌的主动监测:概述与更新。
Curr Treat Options Oncol. 2013 Mar;14(1):97-108. doi: 10.1007/s11864-012-0221-5.
2
LOW RISK PROSTATE CANCER: ACTIVE TREATMENT OR ACTIVE SURVEILLANCE?低风险前列腺癌:积极治疗还是主动监测?
Acta Clin Croat. 2015 Sep;54(3):337-44.
3
An evidence review of active surveillance in men with localized prostate cancer.局限性前列腺癌男性患者主动监测的证据综述。
Evid Rep Technol Assess (Full Rep). 2011 Dec(204):1-341.
4
Active surveillance for low-risk prostate cancer.低风险前列腺癌的主动监测。
F1000 Med Rep. 2012;4:16. doi: 10.3410/M4-16. Epub 2012 Aug 1.
5
Role of active surveillance in the management of localized prostate cancer.主动监测在局限性前列腺癌管理中的作用。
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):202-6. doi: 10.1093/jncimonographs/lgs032.
6
Prostate cancer overdiagnosis and overtreatment.前列腺癌过度诊断与过度治疗。
Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):204-9. doi: 10.1097/MED.0b013e328360332a.
7
Overdiagnosis and overtreatment of prostate cancer.前列腺癌的过度诊断与过度治疗。
Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9.
8
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.在真实队列中对前列腺癌进行主动监测:比较 PRIAS 合格和 PRIAS 不合格患者的结局。
Eur Urol Oncol. 2018 Aug;1(3):231-237. doi: 10.1016/j.euo.2018.03.015. Epub 2018 May 15.
9
[Active surveillance is a useful strategy in the management of patients with low-risk prostate cancer].主动监测是低风险前列腺癌患者管理中的一种有用策略。
Ugeskr Laeger. 2014 Dec 8;176(50).
10
[Active surveillance is a useful strategy in the management of patients with low-risk prostate cancer].主动监测是低风险前列腺癌患者管理中的一种有用策略。
Ugeskr Laeger. 2015 Apr 27;177(18):841-5.

引用本文的文献

1
Prostate cancer biomarkers: from early diagnosis to precision treatment.前列腺癌生物标志物:从早期诊断到精准治疗。
Clin Transl Oncol. 2024 Oct;26(10):2444-2456. doi: 10.1007/s12094-024-03508-2. Epub 2024 May 14.
2
Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients.基于 18F-胆碱 PET/CT 的影像组学分析预测高危前列腺癌的疾病转归:94 例患者机器学习特征分类的探索性研究。
Eur Radiol. 2021 Jul;31(7):4595-4605. doi: 10.1007/s00330-020-07617-8. Epub 2021 Jan 14.
3
The role of radiomics in prostate cancer radiotherapy.

本文引用的文献

1
Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.低危或中危局部前列腺癌初始期待管理患者的结局。
BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.
2
Cancer overdiagnosis and overtreatment.癌症过度诊断和过度治疗。
Curr Opin Urol. 2012 May;22(3):203-9. doi: 10.1097/MOU.0b013e32835259aa.
3
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.
放射组学在前列腺癌放射治疗中的作用。
Strahlenther Onkol. 2020 Oct;196(10):900-912. doi: 10.1007/s00066-020-01679-9. Epub 2020 Aug 21.
4
Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.磁共振成像引导下的前列腺癌主动监测确认性活检。
JAMA Netw Open. 2019 Sep 4;2(9):e1911019. doi: 10.1001/jamanetworkopen.2019.11019.
5
Quality of Life Among Black Prostate Cancer Survivors: An Integrative Review.黑人前列腺癌幸存者的生活质量:一项综合综述。
Am J Mens Health. 2018 Sep;12(5):1648-1664. doi: 10.1177/1557988318780857. Epub 2018 Jun 21.
6
Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study.减少安大略省东部通过根治性前列腺切除术对前列腺癌的过度治疗:一项基于人群的队列研究。
CMAJ Open. 2018 Apr 30;6(2):E197-E201. doi: 10.9778/cmajo.20170149.
7
Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.循环mRNA和miRNA作为前列腺癌诊断和预后的候选标志物。
PLoS One. 2017 Sep 14;12(9):e0184094. doi: 10.1371/journal.pone.0184094. eCollection 2017.
8
Prostate Cancer Patient Perspectives on the Use of Information in Treatment Decision-Making: A Systematic Review and Qualitative Meta-synthesis.前列腺癌患者对治疗决策中信息使用的看法:一项系统综述与定性元分析
Ont Health Technol Assess Ser. 2017 May 1;17(7):1-32. eCollection 2017.
9
Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment.局限性前列腺癌的Prolaris细胞周期进展检测:一项卫生技术评估
Ont Health Technol Assess Ser. 2017 May 1;17(6):1-75. eCollection 2017.
10
Genetic variants of the CYP1B1 gene as predictors of biochemical recurrence after radical prostatectomy in localized prostate cancer patients.CYP1B1基因的遗传变异作为局限性前列腺癌患者根治性前列腺切除术后生化复发的预测指标。
Medicine (Baltimore). 2016 Jul;95(27):e4066. doi: 10.1097/MD.0000000000004066.
美国国立卫生研究院现状科学会议:主动监测在局限性前列腺癌男性管理中的作用。
Ann Intern Med. 2012 Apr 17;156(8):591-5. doi: 10.7326/0003-4819-156-8-201204170-00401. Epub 2012 Feb 20.
4
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.度他雄胺在局限性前列腺癌管理中的应用:REDEEM 随机、双盲、安慰剂对照试验。
Lancet. 2012 Mar 24;379(9821):1103-11. doi: 10.1016/S0140-6736(11)61619-X. Epub 2012 Jan 24.
5
Should we really consider Gleason 6 prostate cancer?我们真的应该将 Gleason 6 级前列腺癌纳入考虑范围吗?
BJU Int. 2012 Mar;109(5):645-6. doi: 10.1111/j.1464-410X.2011.10854.x. Epub 2011 Dec 22.
6
Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial.前列腺癌主动监测与健康相关的生活质量:前瞻性试验芬兰部分的结果。
BJU Int. 2012 Jun;109(11):1614-9. doi: 10.1111/j.1464-410X.2011.10677.x. Epub 2011 Nov 1.
7
Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study.观察等待和生活质量在前列腺癌幸存者中的医生健康研究。
J Urol. 2011 Nov;186(5):1862-7. doi: 10.1016/j.juro.2011.06.058. Epub 2011 Sep 23.
8
Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer.主动监测早期前列腺癌男性的连续活检中肿瘤体积的变化。
J Urol. 2011 Nov;186(5):1825-9. doi: 10.1016/j.juro.2011.06.055. Epub 2011 Sep 25.
9
Early prostate cancer--treat or watch?早期前列腺癌——治疗还是观察?
N Engl J Med. 2011 Aug 11;365(6):569. doi: 10.1056/NEJMc1106325.
10
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.根治性前列腺切除术或观察等待后长期生活质量结局:斯堪的纳维亚前列腺癌群组 4 随机试验。
Lancet Oncol. 2011 Sep;12(9):891-9. doi: 10.1016/S1470-2045(11)70162-0. Epub 2011 Aug 5.